Meta-analysis results indicate protective effect for omega-3 against heart attack and sudden death
Tuesday, August 27, 2013. The results of a meta-analysis reported in the August 2013 issue of the journal Atherosclerosis Supplements add evidence to the benefit of omega-3 polyunsaturated fatty acid supplementation for the prevention of cardiac death, sudden death and heart attack in cardiovascular disease patients.
For their analysis, researchers in Milan selected 11 randomized, double-blinded trials involving a total of 15,348 men and women with a history of cardiovascular disease. Participants received a placebo or at least one gram omega-3 fatty acids per day. Eight hundred twenty-five patients died over the course of the trials, which ranged in length from one to five years.
The risks of cardiac death and sudden death were significantly reduced by 32% and 33% among subjects who received the supplements in comparison with the placebo group. Furthermore, the risk of heart attack was reduced by 25% among those who received omega-3, and there was an 11% lower risk of all-cause mortality (although the latter did not reach statistical significance).
Omega-3 fatty acid supplements may provide several cardiovascular benefits, including protection against arrhythmia, reduction of blood clots, stabilization of plaque, vasodilation, and lipid reduction. The authors suggest that the lack of effect observed in some trials could be due to the concurrent use of statin drugs or other medications by the participants.
"We chose to include randomized, double-blind, placebo controlled trials investigating the effect of omega-3 fatty acid administration to patients with existing cardiovascular disease (the group most likely to benefit from their use), through administration of sufficiently high doses, and for time windows sufficiently long to manifest their cardiovascular preventive action," Manuela Casula and her associates write.
"Our results supply evidence that long-term effect of high dose omega-3 fatty acid supplementation may be beneficial for the onset of cardiac death, sudden death and myocardial infarction among patients with a history of cardiovascular disease," they conclude.
The results of a study presented on May 20, 2012 at the World Congress of Cardiology held in Dubai revealed a protective effect for omega-3 fatty acids against some of the adverse cardiovascular effects of smoking.
Greek researchers divided 16 healthy, young smokers to receive two grams per day omega-3 fatty acids or a placebo for four weeks. The participants' arterial health and aortic stiffness were evaluated before and after smoking at the beginning of the study and at the end of the treatment period.
Before treatment, cigarette smoking resulted in adverse changes in arterial function, which were improved after four weeks of omega-3 fatty acid treatment. The placebo group, however, experienced no significant differences.
"These findings suggest that omega-3 fatty acids inhibit the detrimental effects of smoking on arterial function, which is an independent prognostic marker of cardiovascular risk," commented Dr Gerasimos Siasos of the University of Athens Medical School's Hippokration General Hospital. "The cardioprotective effects of omega-3 fatty acids appear to be due to a synergism between multiple, intricate mechanisms involving anti-inflammatory and antiatherosclerotic effects. Furthermore, AHA recommends that people without documented history of coronary heart disease should consume a variety of fish (preferably oily – rich in omega-3 fatty acids) at least twice per week."
"The World Heart Federation strongly encourages all smokers to quit," added Dr Kathryn Taubert, who is the Chief Science Officer at the World Heart Federation. "The only way to protect your body from the harmful effects of tobacco is to stop smoking. We encourage all people, both smokers and nonsmokers, to eat healthy diets, which includes foods rich in omega-3 fatty acids."
The Life Extension Foundation® exists to provide its members with information and access to things they need to stay younger and healthier longer. Join the Life Extension Foundation for as little as $6.95 a month.
Your membership fee will help fund ongoing research on cures for the diseases of aging ... and eventually for aging itself. This small investment today will help you enjoy many more tomorrows. It will also provide you with these important member benefits.
25%–50% savings on over 350 science-based, premium-quality Life Extension supplements
Phone access to an integrative team of health advisors
Disease Prevention and Treatment book
Product Credit up to $300 accompanies the renewal of an annual membership
Monthly issues of Life Extension Magazine®
Savings on individual blood tests and comprehensive blood panels
Many experts now believe fucoidan is one of the key nutrients responsible for the exceptionally long, healthy lives enjoyed in Okinawa, Japan … which for decades boasted the world's highest concentration of centenarians (individuals at least a century old).
Maritech® 926 fucoidan is sourced from hand-harvested, wild seaweed from the pristine ocean waters of Patagonia. A cutting-edge water extraction process ensures fucoidan's delicate molecular structure is delivered intact, to provide the critical nutritional benefit of Undaria pinnatifida, the species of seaweed used in a majority of scientific fucoidan studies.
Maritech® 926 is a registered trademark of Marinova Pty Ltd.
As people age, bodily changes can occur due to the production of cell-signaling chemicals, known as pro-inflammatory cytokines, as well as the imbalances of hormone-like messengers called prostaglandins and leukotrienes. Maintaining optimal health involves inhibiting these inflammatory factors.
Boswella from Hervedics is an extract of the resin of the Boswellia serrata tree which grows in India. Boswellic acids are effective at blocking the synthesis of pro-inflammatory 5-lipoxygenase products and may also mediate other inflammatory actions by inhibiting cyclooxygenases, preferentially COX-1.